Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OVX836

Vaccine · Immune activation · developed by Osivax

Phase 2 Most advanced trial (none active)
2 Registered trials

What is OVX836?

OVX836 is an agent given as a single intramuscular administration on Day 1 in trials in influenza and vaccine-preventable diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Osivax
In trials of
HRMY
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06582277 Phase 2 Vaccine-Preventable Diseases Completed HRMY
NCT05284799 Phase 2 Influenza Completed HRMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

InfluenzaVaccine-Preventable Diseases

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.